Market access of Spinraza (Nusinersen) for spinal muscular atrophy: intellectual property rights, pricing, value and coverage considerations

scientific article published on 7 September 2017

Market access of Spinraza (Nusinersen) for spinal muscular atrophy: intellectual property rights, pricing, value and coverage considerations is …
instance of (P31):
scholarly articleQ13442814
editorialQ871232

External links are
P6179Dimensions Publication ID1091497563
P356DOI10.1038/GT.2017.79
P698PubMed publication ID28880019

P50authorSteven SimoensQ87433253
P2093author name stringI Huys
P2860cites workSpinal muscular atrophy.Q33345749
Pricing and reimbursement of orphan drugs: the need for more transparencyQ34193502
Structure and organization of the human survival motor neurone (SMN) geneQ34400462
Big win possible for Ionis/Biogen antisense drug in muscular atrophyQ34542348
Paying for the Orphan Drug System: break or bend? Is it time for a new evaluation system for payers in Europe to take account of new rare disease treatments?Q36639084
Advanced therapy medicinal products: current and future perspectivesQ36840842
Rare diseases, orphan drugs and their regulation: questions and misconceptionsQ43814369
A pilot study of multicriteria decision analysis for valuing orphan medicines.Q48119113
Resveratrol suppressed seizures by attenuating IL-1β, IL1-Ra, IL-6, and TNF-α in the hippocampus and cortex of kindled miceQ48214403
Classification of spinal muscular atrophiesQ72423037
An Update on Clinical And Economic Evidence Requirements for Advanced-Therapy Medicinal Products in EuropeQ89240473
Nusinersen, an antisense oligonucleotide drug for spinal muscular atrophyQ89262117
Fresh from the biotech pipeline-2016Q89947270
P433issue9
P921main subjectmuscular atrophyQ2844600
intellectual propertyQ131257
spinal muscular atrophyQ580290
intellectual property rightQ108855835
P304page(s)539-541
P577publication date2017-09-07
P1433published inGene TherapyQ15763095
P1476titleMarket access of Spinraza (Nusinersen) for spinal muscular atrophy: intellectual property rights, pricing, value and coverage considerations
P478volume24

Reverse relations

cites work (P2860)
Q60046512Barriers for Access to New Medicines: Searching for the Balance Between Rising Costs and Limited Budgets
Q49922954Genetic therapies for spinal muscular atrophy type 1.
Q99417440RNA Drugs and RNA Targets for Small Molecules: Principles, Progress, and Challenges
Q90309160RNA therapy: Are we using the right molecules?
Q91975720The Iterative Development of Medicines Through the European Medicine Agency's Adaptive Pathway Approach

Search more.